-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $9

Benzinga·11/17/2026 13:17:42
Listen to the news
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $11 to $9.